RAB2A, member RAS oncogene familyGenealiases: LHX · RAB2
Q-omics provides the consensus-scored RAB2A profile across patient tissues and cancer cell-line models. RAB2A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RAB2A is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, RAB2A protein abundance shows 19,399 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, THCA, and GBM as cancer lineages where RAB2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB2A survival associations across molecular data types. RAB2A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB2A RNA expression–survival associations across cancer types. High RAB2A expression shows unfavorable associations in UVM, UCEC, HNSC, BRCA and CESC, but favorable associations in LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RAB2A RNA expression.
This table summarizes RAB2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB2A shows lower tumor expression in THCA and higher tumor expression in LIHC, HNSC, STAD, LUAD and BRCA. The THCA box plot shows higher RAB2A RNA expression in normal versus tumor tissue (log2 FC = −0.659, t-test p < 0.001).
This table shows molecular features associated with RAB2A in patient tissues and cancer cell lines. In patient samples, RAB2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
